Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Utility of a Diagnostic Time-Out to Evaluate an Atypical Pneumonia

Zaw Hlyan Phyo, MS, Che Matthew Harris, MD, MS, Amteshwar Singh, MD, MEHP, Susrutha Kotwal, MD

Johns Hopkins University School of Medicine, Baltimore, Md.

PRESENTATION

A 48-year-old woman with no significant medical history presented to the emergency department with fever, non-productive cough, and shortness of breath for 4 days. She reported ongoing dyspnea on exertion over 1 month, which rapidly progressed in the days leading up to her presentation. She also reported experiencing watery, non-bloody diarrhea, night sweats, and ageusia in the past month. A review of systems was negative for weight loss, headache and neck pain, chest pain, rash, lymphadenopathy, arthralgia, dysuria, and change in urinary frequency. The patient worked as a meat cutter at a local grocery store in Maryland and did not report any sick contacts, recent travel, or illicit substance use. Her vaccinations were up to date, including the coronavirus disease (COVID-19) vaccine, which she received 2 months prior to presentation.

ASSESSMENT

She was febrile (temperature 38.1°C), tachypneic with oxygen saturation of 88% and tachycardic (heart rate 117 beats/min, blood pressure 106/71 mm Hg). A pulmonary exam was notable for diffuse, coarse crackles bilaterally, and she was in respiratory distress (respiratory rate 20 breaths/min), requiring 2 liters of supplemental oxygen. Wheezing, intercostal retractions, and fingernail clubbing were absent. Her complete blood count showed hemoglobin of 9.9 g/dL (reference 12-16 g/dL) and normal white blood cell count with neutrophilia (83.6%, reference 40%-60%) and lymphopenia (5.5%, reference 20%-40%) (Table). Serum electrolytes, liver enzymes, blood urea nitrogen, and creatinine were within normal limits. Inflammatory markers, such as C-reactive protein (14.6 mg/dL, reference < 10 mg/dL) and erythrocyte sedimentation rate (114 mm/h, reference < 29 mm/h), were elevated, and a COVID-19 nasal swab was negative. A chest x-ray demonstrated prominent central bronchovascular markings (Figure 1A). A computed tomography scan without contrast of the thorax revealed diffuse, symmetric bilateral ground-glass opacities most prominent at the lung bases (Figure 1B). Given that the presentation was most consistent with community-acquired viral or atypical pneumonia, she was admitted to the hospital and was initiated on intravenous antibiotics for pneumonia. The diagnostic workup included 2 sets of peripheral blood cultures, sputum culture, Streptococcus pneumoniae and Legionella urine antigen and a comprehensive respiratory virus panel test (including a repeat SARS-CoV-2), all of which were negative.

After 2 days, her fever persisted with a maximum temperature of 39.4°C, and her clinical status deteriorated with progressive fatigue, intermittent episodes of confusion, and increasing oxygen requirement up to 6 liters. A repeat computed tomography scan of her lungs to evaluate for pulmonary embolism and progression of pneumonia revealed worsening lung opacities but no evidence of pulmonary embolism (Figure 1B).

DIAGNOSIS

The initial diagnosis of pneumonia seemed an adequate fit given the opacities on chest imaging and the clinical syndrome that included fever, dyspnea, and cough. Her history of extrapulmonary symptoms (diarrhea, night sweats, ageusia) suggested an atypical pneumonia. Because of the current pandemic, we were most suspicious of COVID-19 pneumonia; however, this was ruled out by 2 polymerase chain reaction tests performed a day apart. The patient’s worsening status then prompted a diagnostic time-out, and reevaluation of her history, which revealed that her husband was human immunodeficiency virus (HIV) positive and non-adherent to antiretroviral therapy. Subsequently, a hypothesis driven
physical exam revealed pseudomembranous, white patches on the tongue most consistent with oral candidiasis (Figure 2), driving us to consider immunocompromised states in our differential diagnosis. The HIV polymerase chain reaction test returned positive with a CD4 count of 7 (normal 500-1200 cells per cubic millimeter, cells/mm³) and a lactate dehydrogenase level that was elevated (Table).

A diagnosis of *Pneumocystis jirovecii* pneumonia was confirmed by bronchoscopy with bronchoalveolar lavage, which is the gold-standard diagnostic test (sensitivity of 90%-98% and specificity of 83%-96%). Given an acute change in the patient’s mental status, lumbar puncture and head imaging were also performed to rule out meningencephalitis. Brain magnetic resonance imaging revealed non-specific, diffuse ischemic changes, and a lumbar puncture was negative for infection in the cerebrospinal fluid.

*Pneumocystis jirovecii* pneumonia is a life-threatening fungal pneumonia caused by *P jirovecii*, which typically occurs in immunocompromised individuals and remains a prevalent opportunistic infection in HIV-infected individuals, comprising 20% of pulmonary infiltrates of infectious etiology. Other risk factors for this opportunistic infection include malignancy, hematopoietic stem cell or solid organ transplantation, and medications such as glucocorticoids or immunosuppressive therapies (eg, cyclosporine). *Pneumocystis* is thought to be transmitted through airborne droplets. Immunocompetent individuals, although typically not affected, may serve as reservoirs for spread to immunocompromised hosts.

*Pneumocystis jirovecii* pneumonia in an HIV-infected individual commonly presents with progressive dyspnea in the setting of fever and non-productive cough. It typically appears on chest radiograph as bilateral perihilar interstitial infiltrates (referred to as “ground-glass opacities”). Detection of *Pneumocystis jirovecii* on bronchoalveolar lavage is the gold-standard for diagnosis and provides the highest diagnostic yield in infected individuals. Trimethoprim-sulfamethoxazole is the most effective treatment for *P jirovecii* pneumonia; the adjunctive use of corticosteroids reduces mortality and the need for mechanical ventilation in patients with hypoxemia (partial pressure of arterial oxygen less than 70 mm Hg or alveolar-arterial gradient above 35).

| Lab Value                  | Reference          | Presentation | Discharge |
|---------------------------|--------------------|--------------|-----------|
| **Complete Blood Count**  |                    |              |           |
| Red Blood Cell Count      | 4.00 - 5.20 (K/mm³) | 3.6          | 3.56      |
| Hemoglobin                | 12 - 16 (g/dL)     | 9.9          | 10.6      |
| White Blood Cell Count    | 4.50 - 11.00 (K/mm³) | 7.07        | 4.8       |
| Neutrophil                | 40 - 60 (%)        | 83.6         | 77.6      |
| Lymphocyte                | 20 - 40 (%)        | 5.5          | 7.3       |
| Absolute Neutrophil Count | 1.50 - 7.80 (K/mm³) | 5.89        | 3.73      |
| Absolute Lymphocyte Count | 1.10 - 4.80 (K/mm³) | 0.39        | 0.35      |
| **Complete Metabolic Panel** |                   |              |           |
| Sodium                    | 136 - 145 (mmol/L) | 139         | 138       |
| Potassium                 | 3.5 - 5.1 (mmol/L) | 4           | 3.8       |
| Chloride                  | 98 - 107 (mmol/L)  | 107         | 106       |
| Carbon Dioxide            | 21 - 32 (mmol/L)   | 26          | 23        |
| Urea Nitrogen             | 7 - 18 (mg/dL)     | 7           | 19        |
| Creatinine                | 0.60 - 1.30 (mg/dL) | 1         | 0.92      |
| Glucose                   | 71 - 99 (mg/dL)    | 94          | 78        |
| Calcium                   | 8.5 - 10.1 (mg/dL) | 8.5        | 8.5       |
| **Liver Enzymes**         |                    |              |           |
| Alkaline Phosphatase      | 45 - 117 (U/L)     | 116         | 75        |
| Aspartate Amino Transferase | 3 - 37 (U/L)     | 69          | 28        |
| Alanine Amino Transferase | 6 - 65 (U/L)       | 32          | 19        |
| **Inflammatory Markers**  |                    |              |           |
| Erythrocyte Sedimentation Rate | 4 - 25 (mm/h) | 114         | -         |
| C-Reactive Protein        | <0.29 (mg/dL)      | 14.6        | -         |
| **Other**                 |                    |              |           |
| HIV-1/2 Antibodies        | Nonreactive        | HIV-1 Reactive |
| CD3+ lymphocytes          | 51 - 91 (%)        | 58.2        |
| CD4+ lymphocytes          | 32 - 68 (%)        | 2           |
| Absolute CD4+ lymphocytes | 458 - 1344/mm³     | 7           |
| Lactate Dehydrogenase     | 100 - 190 U/L      | 471         |           |
Utility of Diagnostic Time-Out

According to the dual process theory of decision-making, physicians rely on 2 types of reasoning models in the diagnosis and management of patients: analytic and intuitive. In the analytic model, physicians employ a time-consuming process in generating a broad differential diagnosis and a deliberate evaluation of hypotheses. In contrast, the intuitive model relies on pattern-recognition refined by knowledge of typical and atypical presentations and clinical experience. Through this case report, we offer an approach

Figure 1  (A) Chest x-ray in the posteroanterior view showing central bronchovascular markings on the day of presentation and hospital day 3. Chest computed tomography. (B) in the transverse plane showing diffuse and symmetric ground-glass opacities in bilateral lungs at presentation and worsening of ground-glass opacities bilaterally on hospital day 3.
Figure 2  Pseudomembranous, white patches on the patient’s tongue most consistent with oral candidiasis.

Figure 3  Schema for developing and reflecting on the working diagnosis.
to improve the diagnostic process by utilizing a diagnostic time-out (Figure 3). This approach enables the clinician to reflect on potential gaps in data gathering, the impact of cognitive biases, and embarking on plans with structured follow-ups. Returning to the bedside to gather a hypothesis-driven history and to perform a comprehensive exam may prompt the discovery of key findings, as illustrated by the patient’s oropharyngeal candidiasis and a history of HIV infection in her spouse.

MANAGEMENT

The patient was initiated on a 21-day course of oral trimethoprim-sulfamethoxazole (800 mg trimethoprim, 160 mg sulfamethoxazole) twice a day and a prednisone taper, in addition to anti-retroviral therapy, in accordance with current Centers for Disease Control and Prevention guidelines for patients with a CD4 count less than 200 cells/mm³. Two weeks after discharge at a follow-up appointment with her primary care provider, she reported resolution of symptoms and adherence to anti-retroviral therapy.

In conclusion, this case demonstrates that a diagnostic time-out can help avoid delay in appropriate care and consequently improve the patient’s clinical trajectory.

References

1. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200(7):e45–67.
2. Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J, 39; 2012 Mar. p. 2012 Mar730–45.
3. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34 (8):1098–107.
4. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004 Jun 10;350(24):2487–98.
5. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS. 1989:140(5):1204-1209.
6. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 1990;323(21):1444–50.
7. Balogh EP, Miller BT, Ball JR. THE NATIONAL ACADEMIES PRESS Improving Diagnosis in Health Care. Published online; 2015.
8. Ely JW, Gruber ML, Croskerry P. Checklists to reduce diagnostic errors. Acad Med 2011;86(3):307–13.
9. Kaplan JE, Masur H, Holmes KK, USPHS; Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51(RR-8):1–52.